1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 13,800 | 14,100 | 15:44 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 06.08. | Stifel reiterates Buy rating on Spyre stock with $71 price target | 3 | Investing.com | ||
| 06.08. | Stifel bestätigt Kaufempfehlung für Spyre mit Kursziel von 71 Dollar | 1 | Investing.com Deutsch | ||
| 05.08. | Spyre Therapeutics GAAP EPS of -$0.49 beats by $0.28 | 4 | Seeking Alpha | ||
| 05.08. | Spyre Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| SPYRE THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 05.08. | Spyre Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 05.08. | Spyre Therapeutics, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 09.07. | IBM unveils Power11 portfolio, announces Spyre AI chip integration | 5 | DatacenterDynamics | ||
| 17.06. | Spyre reports results from early stage TL1A antibody trials | 3 | Seeking Alpha | ||
| 17.06. | Spyre reports positive results for anti-TL1A antibodies in trials | 2 | Investing.com | ||
| 17.06. | Spyre Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 17.06. | Spyre Therapeutics, Inc.: Spyre Therapeutics Announces Positive Interim Phase 1 Results for Two Next-Generation TL1A Antibody Programs, and Provides Clinical Development Updates Expected to Deliver 9 Phase 2 Readouts | 440 | PR Newswire | SPY002 and SPY072 were well tolerated, exhibited PK that supports quarterly or less frequent dosing, and fully engaged TL1A through up to 20 weeks of follow-up;... ► Artikel lesen | |
| 03.06. | Guggenheim reiterates Buy rating on Spyre stock citing pipeline progress | 2 | Investing.com | ||
| 02.06. | Spyre Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 09.05. | Spyre Therapeutics GAAP EPS of -$0.60 | 1 | Seeking Alpha | ||
| 08.05. | Spyre Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 08.05. | Spyre Therapeutics, Inc.: Spyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update | 113 | PR Newswire | On track for mid-year initiations of planned Phase 2 studies in ulcerative colitis ("UC") and rheumatoid arthritis ("RA"), providing for 7+ proof-of-concept readouts... ► Artikel lesen | |
| 08.05. | Spyre Therapeutics, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 05.05. | Spyre Presents Promising SPY001 IBD Data And Combination Therapy Results At DDW 2025 | 1 | RTTNews | ||
| 28.03. | BTIG maintains Spyre stock Buy rating, $70 target | 15 | Investing.com | ||
| 27.03. | Spyre Therapeutics, Inc.: Spyre Therapeutics Announces First Participant Dosed in Phase 1 Trial of SPY003, its Novel Half-life Extended IL-23 Antibody | 186 | PR Newswire | Preclinical data demonstrates that SPY003 is highly potent and has potential forquarterly or biannual dosing, suggesting opportunity for improved efficacy andconvenience... ► Artikel lesen |
1 2 Weiter >>
32 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ORUKA THERAPEUTICS | 11,800 | 0,00 % | Oruka Therapeutics, Inc.: Oruka Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update | First patients dosed in the EVERLAST-A Phase 2a trial of ORKA-001, with data expected in 2H 2026 ORKA-001 Phase 1 data and EVERLAST-A design to be presented at EADV in September 2025 ORKA-002 Phase... ► Artikel lesen | |
| PALVELLA THERAPEUTICS | 36,600 | 0,00 % | This Palvella Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday | ||
| DIANTHUS THERAPEUTICS | 16,900 | +4,32 % | Dianthus Therapeutics GAAP EPS of -$0.88, revenue of $193M | ||
| JOUNCE THERAPEUTICS | - | - | IBM's Red Hat acquires stealth Israeli startup Jounce for $20M to bolster AI cloud stack | ||
| LENZ THERAPEUTICS | 36,320 | 0,00 % | LENZ Therapeutics, Inc.: LENZ Therapeutics and Lotus Pharmaceutical Announce Exclusive License and Commercialization Agreement for LNZ100 in the Republic of Korea and Southeast Asia | SAN DIEGO and TAIPEI, Taiwan, May 09, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ) and Lotus Pharmaceutical Co., Ltd. ("Lotus", TWSW Stock Code: 1795) today announced an exclusive... ► Artikel lesen | |
| TOURMALINE BIO | 21,380 | 0,00 % | Tourmaline Bio, Inc.: Tourmaline Bio Reports Second Quarter 2025 Financial Results and Recent Business Highlights | - Reported positive topline results from the ongoing Phase 2 TRANQUILITY trial of pacibekitug in May 2025, demonstrating rapid, deep, and durable reductions in high-sensitivity C-reactive protein... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 46,230 | 0,00 % | Aktien New York: Erholungspfad wieder aufgenommen - Apple ziehen stark an | NEW YORK (dpa-AFX) - Die US-Börsen haben am Mittwoch nach dem etwas schwächeren Vortag wieder den Weg nach oben eingeschlagen. Für Bewegung sorgten positiv aufgenommene Nachrichten zu Apple sowie Unternehmensberichte.... ► Artikel lesen | |
| 180 LIFE SCIENCES | 10,270 | 0,00 % | 180 Life Sciences setzt auf Ethereum - Milliardenwechsel in Geschäftsstrategie | Die 180 Life Sciences Corp. (Börsenkürzel: ATNF) hat bekanntgegeben, inzwischen 82.186 Ether-Token zu halten - ein Bestand, der zum 11. August 2025 rund 349 Millionen US-Dollar wert war. Der durchschnittliche... ► Artikel lesen | |
| BEAM THERAPEUTICS | 16,860 | 0,00 % | Beam Therapeutics Reports Second Quarter 2025 Financial Results and Provides Update on BEAM-302 Development Progress in Alpha-1 Antitrypsin Deficiency (AATD) | With 17 Patients Dosed in the Phase 1/2 Trial, BEAM-302 Continues to Demonstrate Durable Correction of the Disease-causing Mutation, Restoration of AAT Physiology, and a Well Tolerated Safety Profile... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 5,410 | 0,00 % | RXRX Q2 Loss Wider Than Expected, Revenues Rise Y/Y, Stock Down | ||
| EVOTEC | 6,460 | -1,82 % | DAX-Check LIVE: Brenntag, Evotec, Jenoptik, Patrizia, Renk, Sixt | Die US-Inflationsdaten gaben dem DAX nur geringe Impulse und konnten die Anleger nicht aus der Reserve locken. Am Dienstag rutschte der deutsche Leitindex nach anfänglichen Gewinnen zeitweise unter... ► Artikel lesen | |
| HARMONY BIOSCIENCES | 35,470 | 0,00 % | Mizuho raises Harmony Biosciences stock price target to $50 on increased confidence | ||
| SUMMIT THERAPEUTICS | 25,680 | 0,00 % | Evercore ISI hebt Kursziel für Summit Therapeutics auf 34 US-Dollar an | ||
| JANUX THERAPEUTICS | 24,270 | 0,00 % | Janux Therapeutics, Inc. - 10-Q, Quarterly Report | ||
| STRUCTURE THERAPEUTICS | 18,740 | 0,00 % | Structure Therapeutics Inc.: Structure Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights | Topline data from oral small molecule GLP-1 receptor agonist aleniglipron ACCESS and ACCESS II studies on track for year-end 2025 readouts Aleniglipron clinical development program expanded to optimize... ► Artikel lesen |
Das Unternehmen SPYRE THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -5,84 % bei einem Aktienkurs von 12,900 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SPYRE THERAPEUTICS INC finden Sie auf Wallstreet Online.